The War Over Cheaper Ozempic Won't End Well for Some Investors
26/06/2024 07:00Wall Street Journal
Once Eli Lilly and Novo Nordisk increase the supply of weight-loss medications, companies such as Hims & Hers may find it trickier to sell compounded versions of the drugs.